Diana Ernst, RPh, Author at Endocrinology Advisor - Page 2 of 6
christineeicher

christineeicher

All articles by christineeicher

FDA Approves First-in-Class Sclerostin-Inhibitor for Postmenopausal Women at High Risk for Fracture

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Soliqua 100/33 Indication Expanded to Include T2D Patients Uncontrolled on Oral Antidiabetic Agents

The Food and Drug Administration (FDA) has approved an expanded indication for Soliqua 100/33 to include use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are uncontrolled on oral antidiabetic agents, in addition to those inadequately controlled on basal insulin or lixisenatide.

Next post in Type 2 Diabetes